![](https://monteverdelaw.com/wp-content/uploads/case-logo/sierra-oncology-inc.png)
Sierra Oncology, Inc. (SRRA), relating to its proposed acquisition by GlaxoSmithKline plc. Under the terms of the agreement, SRRA shareholders will receive $55.00 in cash per share they own.
Sierra Oncology, Inc. (SRRA), relating to its proposed acquisition by GlaxoSmithKline plc. Under the terms of the agreement, SRRA shareholders will receive $55.00 in cash per share they own.